GLP-1 Agonists for NASH Treatment: New Clinical Evidence Reveals Surprising Results Introduction Non-alcoholic fatty liver disease (NAFLD) has emerged as a major global health concern, affecting approximately one in four individuals worldwide. It is now recognized as the most common cause of
Tag: Glucagon-like peptide-1
